Policy & Regulation
Provention Bio names new senior vice president of Clinical Development
21 August 2019 -

Provention Bio Inc (Nasdaq: PRVB), a clinical stage biopharmaceutical company involved in intercepting and preventing immune-mediated diseases, announced yesterday that it has named Sherron Kell, MD, MPH as its new senior vice president of Clinical Development.

In the new role, Dr Kell will lead the PRV-031 (teplizumab) program, including the oversight of the Phase three PROTECT study and clinical support of anticipated regulatory submissions, and will report to Dr Eleanor (Leni) Ramos, chief medical and operating officer.

Dr Kell most recently served as vice president at Impax Pharmaceuticals. Previously, she was senior director, Clinical R&D at Johnson & Johnson, and scientific director at Novartis Pharmaceuticals.

Login
Username:

Password: